American Association for Cancer Research
can-22-0536_table_s1_suppst1.xlsx (38.55 kB)

Table S1 from An In Vivo CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression

Download (38.55 kB)
posted on 2023-06-15, 08:20 authored by Xun-Xi Lu, Wen-Xiao Yang, Yu-Chen Pei, Hong Luo, Xiao-Guang Li, Yun-Jin Wang, Guo-Liang Zhang, Hong Ling, Zhi-Ming Shao, Xin Hu

Table S1. Gene list of the CRISPR/Cas9 library.


National Natural Science Foundation of China (NSFC)

Shanghai Science and Technology Innovation Action Plan



Dysregulation of RNA-binding proteins (RBP) is one of the characteristics of cancer. Investigating the biological functions and molecular mechanisms of abnormal RBPs can help uncover new cancer biomarkers and treatment strategies. To identify oncogenic RBPs in triple-negative breast cancer (TNBC), we employed an in vivo CRISPR screen and a TNBC progression model, which revealed small nuclear ribonucleoprotein polypeptide C (SNRPC), a subunit of the U1 small nuclear ribonucleoprotein particle (U1 snRNP), as a key modulator of TNBC progression. SNRPC was frequently upregulated, which corresponded to poor prognosis in patients with TNBC. SNRPC ablation significantly impaired the proliferation, migration, and invasion of TNBC cells in vitro and in vivo. In addition, SNRPC was essential for the stability of U1 snRNP and contributed to the RNA Pol II–controlled transcriptional program. Knockdown of SNRPC decreased RNA Pol II enrichment on a subset of oncogenes (TNFAIP2, E2F2, and CDK4) and reduced their expression levels. Furthermore, SNRPC deletion was confirmed to inhibit TNBC progression partially through regulation of the TNFAIP2-Rac1–β-catenin signaling pathway. Taken together, this data suggests that SNRPC plays an oncogenic role in TNBC, is a marker of poor prognosis, and may be a valuable therapeutic target for patients with intractable TNBC. A functional CRISPR screen identifies SNRPC as an RNA-binding protein that promotes the aggressiveness of breast cancer by facilitating Pol II–controlled transcription of oncogenes.

Usage metrics

    Cancer Research